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Abstract 
 
Vascular areas of atherosclerotic development persist in a state of inflammation, and any 
further inflammatory stimulus in the subintimal area becomes a pro-atherogenic response; this alters 
the behavior of the artery wall cells and recruits further inflammatory cells. In association with the 
inflammatory response, oxidative events are also involved in the development of atherosclerotic 
plaques. It is now unanimously recognized that lipid oxidation-derived products are key players in 
the initiation and progression of atherosclerotic lesions. 
Oxidized lipids, derived from oxidatively modified low-density lipoproteins (LDL) which 
accumulate in the intima, strongly modulate inflammation-related gene expression, through 
involvement of various signaling pathways. In addition, considerable evidence supports a pro-
atherogenic role of a large group of potent bioactive lipids called eicosanoids, which derive from 
oxidation of arachidonic acid, a component of membrane phospholipids. Of note, LDL lipid 
oxidation products might regulate eicosanoid production, modulating the enzymatic degradation of 
arachidonic acid by clycooxygenases and lipoxygenases; these enzymes might also directly 
contribute to LDL oxidation.    
This review provides a comprehensive overview of current knowledge on signal 
transduction pathways and inflammatory gene expression, modulated by lipid oxidation derived 
products, in the progression of atherosclerosis. 
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Introduction: modulation of inflammatory signaling by oxidized lipid products  
 
It is generally accepted that vascular areas of atherosclerotic progression are in a state of 
persistent inflammation [1,2]. As a consequence, any further inflammatory stimulus in the 
subintimal area automatically becomes a pro-atherogenic stimulus, altering the behavior of the 
intrinsic cells of the artery wall, and recruiting further inflammatory cells that interact to promote 
lesion formation and complications. Of note, leukocytes are present even in the very earliest fatty 
streak lesions [3-8]. The association of hypercholesterolemia with atherosclerosis is also well 
established [9,10]. Given that numerous oxidative events are associated with the development of 
atherosclerotic plaques [11], it is now accepted that oxidized low-density lipoproteins (oxLDLs), 
which accumulate in the intima, play a major role in the initiation and promotion of fatty streaks 
and fibrotic plaques [12,13]. In addition, considerable evidence supports a pro-atherogenic role of 
oxLDLs. The biological effects of oxLDLs are mediated through signaling pathways, especially 
involving receptors, protein kinases, and activation of transcription factors, which in turn stimulate 
the expression of genes involved in oxidative stress and the inflammatory response during 
generation of the atherosclerotic plaque [14,15]. Indeed, oxidative stress and inflammation go hand-
in-hand, because oxidative stress induces the production of inflammatory cytokines, and the 
cytokines in turn induce free radical production. 
The main lipid oxidation products present in oxLDLs, and which may be responsible for 
inflammatory processes, are oxysterols and cholesteryl ester oxidation products, lipid-derived free 
aldehydes and oxidized phospholipids. Another quantitatively important component of oxLDLs, 
alongside the oxidized lipid products proper, are the lysophospholipids, hydrolytic derivatives of 
oxidized phospholipids. Moreover, among the oxidized lipid products implicated in atherogenesis, 
there is a large group of potent bioactive lipids, known as prostanoids, isoprostanoids, and 
leukotrienes, which derive from the oxidation of arachidonic acid, a component of membrane 
phospholipids. All these compounds have been directly linked to the induction and propagation of 
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monocytic subendothelial accumulation, and to other inflammatory reactions associated with 
chronic vascular inflammation. Macrophages in the atheroma may also have a pro-inflammatory 
array of functions, characteristic of M1 macrophages, which produce high levels of effectors such 
as cytokines, chemokines, growth factors, adhesion molecules, and other inflammatory molecules. 
Conversely, accumulating data suggest that oxidized lipids may also have anti-inflammatory 
potential, and could, in certain cases, act as inhibitors of the nuclear factor- B (NF- B)-dependent 
pro-inflammatory cascade [16]. 
This review aims to comprehensively summarize current knowledge on the signal 
transduction pathways, and on inflammatory gene expression modulated by lipid oxidation derived 
products, in the progression of atherosclerosis. 
 
Oxysterols 
 
Oxysterols are 27-carbon atom molecules resulting from non-enzymatic or enzymatic 
oxidation of cholesterol, which may either originate in the blood, cells and tissues, or may derive 
from the diet. Several reviews have comprehensively discussed the sources of major biological 
oxysterols and the routes for their formation [17-24]. In general, biological oxysterols can be 
divided into two main groups: 1) those oxygenated in the sterol ring, mainly at position 7 (e.g. 
7 / -hydroxycholesterol, 7 / -hydroperoxycholesterol, and 7-ketocholesterol), which have non-
enzymatic origin; 2) those oxygenated on the side-chain (e.g. 24S-hydroxycholesterol, 25-
hydroxycholesterol, and 27-hydroxycholesterol) which usually have enzymatic origin. Some 
oxysterols, however, can be produced by either non-enzymatic or enzymatic routes: these include 
25-hydroxycholesterol and 7 -hydroxycholesterol. 
Oxysterols are a large and diverse group of compounds with a multiplicity of biological 
activities; they have been found at increased levels in the plasma of patients with cardiovascular 
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diseases, and within atherosclerotic lesions. Depending on the nature and location of the oxygen 
substitution, oxysterols have distinct effects on the biophysical properties of cell membranes, with 
which they interact faster than does cholesterol, due to higher polarity and poorer membrane 
packing. Besides the impact of oxysterols on the biophysical properties of membranes, endogenous 
cellular oxysterols are thought to drive important functions, by interacting with receptor proteins 
[23,25,26]. In this connection, oxysterols not only participate in basic metabolic processes, but are 
also involved in signaling pathways leading to disease development, through induction of 
inflammation, apoptosis, and fibrosis. 
Being multifunctional molecules, oxysterols appear to exert a number of pro-inflammatory 
effects during the progression of atherosclerosis; however, it is extremely difficult to study all 
routes involved, and the molecular mechanisms whereby oxysterols induce inflammation at the 
transcriptional level are not yet fully elucidated. Oxysterol-dependent gene expression is probably 
regulated by various different transcriptional regulators. In this connection, activation of liver X 
receptors (LXR) can only be induced by a small number of pro-inflammatory oxysterols, acting as 
natural ligands [27], while it has been demonstrated that NF- B or activator protein-1 (AP-1) 
nuclear binding can be induced by a biologically representative oxysterol mixture [28,29]. 
Similarly, the oxysterol-induced metabolic pathways at the translational and post-translational 
levels are still unclear, although mitogen-activated protein kinases (MAPKs) are implicated [28-31]. 
MAPKs include extracellular signaling-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), 
and p38 MAPK, which are involved in several cellular functions, ranging from proliferation to 
differentiation and apoptosis, and which thus play an important role in the pathogenesis of cardiac 
and vascular disease [32]. 
 
Oxysterol-mediated up-regulation of chemokines, inflammatory cytokines and metalloproteinases 
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Oxysterols have been shown to induce the expression of various key inflammatory 
molecules. They stimulate not only the adhesion of leukocytes to the arterial endothelium, but also 
their transmigration to sub-intimal spaces, especially by up-regulating chemotactic cytokines such 
as monocyte chemotactic protein-1 (MCP-1) and interleukin-8 (IL-8).  
Up-regulation of MCP-1 has been reported in U937 promonocytic cells stimulated by a 
biologically relevant oxysterol mixture, through the ERK and NF- B pathways [28].  Macrophages 
isolated from human atherosclerotic plaques produce IL-8, and oxysterols appear to be involved in 
production of this cytokine [33]; IL-8 is up-regulated in human monocytes/macrophages by various 
oxysterols, including 25-hydroxycholesterol (25-OH), 24-hydroxycholesterol (24-OH), 7 -
hydroxycholestetrol (7 -OH), 5 ,6 -epoxycholesterol ( -EPOX), 7-ketocholesterol (7-K), and 
cholestan-3 ,5 ,6 -triol (TRIOL) [34-37]. Using calcium channel blockers, it has been shown that 
both 7 -OH-induced and 25-OH-induced IL-8 secretion by THP-1 cells involves calcium-
dependent activation of c-fos (AP-1) via the ERK1/2 signaling pathway [37].  
The oxysterols 25-OH, 7 -OH and 7-K have been found to stimulate IL-8 expression in 
human macrophages, independently of Toll-like receptor (TLR) signaling, although this pathway 
has been shown to contribute to the inflammatory events occurring during atherosclerosis 
progression [36]. IL-8 production is also induced in Caco2 cells by treatment with 25-OH followed 
by IL-1  stimulation [38]. The chemotactic cytokine IL-8 might be pro-atherogenic, acting not only 
by recruiting leukocytes, but also by inhibiting expression of the tissue inhibitor of 
metalloproteinase-1 (TIMP-1). This event causes an imbalance in the metalloproteinases 
(MMPs)/TIMPs activity ratio, with a consequent excessive degradation of extracellular matrix 
components, followed by destabilization and eventual rupture of the atherosclerotic plaque [39]. In 
this connection, in human promonocytic U937 cells it is reported that an oxysterol mixture of 
composition similar to that detectable in advanced human carotid plaques induces expression and 
synthesis of MMP-9, without affecting its endogenous inhibitors TIMP-1 and TIMP-2. Using 
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antioxidants, or specific inhibitors, or siRNAs, it has been demonstrated that the oxysterol mixture 
induces MMP-9 expression through: i) over-production of reactive oxygen species (ROS), likely by 
NADPH oxidase and mitochondria, ii) up-regulation of MAPKs signaling pathways via protein 
kinase C (PKC), iii) up-regulation of AP-1 and NF- B DNA binding [29].  
Further, in human monocytic cells, 7 -OH and 25-OH, but also to a lesser extent 7-K, are 
potent in vitro inducers of MCP-1, IL-8, IL-1 , tumor necrosis factor-  (TNF- ), macrophage 
inflammatory protein-1  (MIP-1 ), as well as of other inflammatory molecules [31]. The same 
study demonstrated that IL-8 secretion was associated with activation of the ERK1/2 signaling 
pathway [31]. The oxysterols 7-K and 25-OH have also been observed to enhance IL-1 , IL-6, IL-8 
and TNF-  mRNA and secretion levels, in a dose-dependent manner, although to different extents. 
These effects were associated with increased ROS production, through enhanced expression of 
NADPH oxidase; net posphorylation of MAPKs and NF- B activation also occurred [40]. 
Up-regulation of IL-1  is another important event, because this cytokine increases the 
surface expression of endothelial adhesion molecules, by facilitating inflammatory cells’ attachment 
to the artery endothelium. Expression and synthesis of IL-1  were found to be stimulated by 25-OH 
in human macrophages, through involvement of LXR, as well as, but less strongly, by 27-
hydroxycholesterol (27-OH). 25-OH was also capable of potentiating lipopolysaccharide (LPS)-
induced IL-1  secretion [41]. IL-1  secretion was also markedly induced by 7 -OH, 7-K and 7 -
hydroxycholesterol (7 -OH) in human promonocytic cells U937 and U4 [35,42] and in human 
umbilical vein endothelial cells (HUVECs) [43]. 
Increased levels of IL-6 have also been found in human macrophages stimulated with 25-
OH or 27-OH [41]. IL-6 secretion was increased by 7-K treatment in human aorta smooth muscle 
cells (SMCs) through MAPK activation, in particular by p38 MAPK, but also via JNK pathways 
[44]. Furthermore, IL-6 regulates the expression of other inflammatory cytokines, such as IL-1 and 
TNF-  [45]. 
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Expression of TNF-  is stimulated by 25-OH in macrophages, only when the cells were co-
treated with 9-cis-retinoic acid, through heterodimerisation of the LXR [46]. Production of the pro-
inflammatory cytokines TNF-  and IL-1 is also induced by 25-OH in adherent human peripheral 
blood mononuclear leukocytes, through phosphorylation of p38 MAPK [47]. Further, synthesis of 
TNF-  has been reported in human peripheral monocytes and in monocytic THP-1 cells treated 
with 22-hydroxycholesterol (22-OH) [46]. Another effect of 7-K and 25-OH, which may enhance 
the inflammatory response, is inhibition of secretion of IL-10, a key anti-inflammatory cytokine, in 
SMCs [48]. Treatment of vascular SMCs with 7-K enhances synthesis of the vascular endothelial 
growth factor (VEGF) [49].  
 Up-regulation of transforming growth factor 1 (TGF 1), the main pro-fibrogenic cytokine 
contributing to the progression of inflammation and fibrosclerosis within the damaged arterial wall, 
has also been shown to be exerted by a biologically representative oxysterol mixture, in J774.A1 
murine macrophagic cell line [50]. In particular, production of TGF 1 plays a pivotal role in SMC 
chemoattraction and differentiation into myofibroblast-like cells. 25-OH has also been shown to 
increase the expression of basic fibroblast growth factor (bFGF), a strong mitogenic and fibrogenic 
cytokine, in SMC [51]. 
 
Induction of the endothelial inflammatory phenotype 
 
 Oxysterols can contribute to increased expression of several adhesion molecules, which play 
key roles in endothelial adhesion and transmigration of leukocytes. Oxysterols, such as 7-K, 7 -OH 
and 7 -OH, increase the level of adhesion molecules involved in the recruitment of 
immunocompetent cells, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) and E-selectin, in HUVECs [43,52,53]. Moreover, incubation with 
7-K markedly induces ROS-dependent secretion of VCAM-1 in human aortic endothelial cells 
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(ECs) and U937 cells [54]. It has also been shown that 25-OH can augment eicosanoid release from 
cultured ECs and increase endothelial-leukocyte interaction by up-regulating VCAM [55]. 
 It is known that endothelial dysfunction plays a central role in atherosclerosis, and 7-K has 
been found to increase expression of the actin-binding protein profilin-1 in aortic ECs. Up-
regulation of the pro-atherogenic protein profilin-1 appears to occur through activation of a 
transduction molecule known as signal transducer and activator of transcription 3 (STAT3), which 
requires Janus kinase 2 (JAK2) and tyrosine 394 phosphorylation of oxysterol-binding protein-1 
(OSBP-1) [56]. Again, oxysterols can be inserted into the cell membrane, where they modify the 
functions of membrane-bound proteins: 7-K has been found to induce endothelial dysfunction by 
disrupting ion transport by Na/K-ATPase, and to perturb the membrane structure in human ECs. 
For these reasons, this oxysterol-induced effect may contribute to the rigidity of plasma membranes 
[57].  
 
Monocyte differentiation and foam cell formation 
 
 Oxysterols contribute to sustaining inflammation, by favoring monocyte differentiation into 
macrophages. It has been shown that a biologically compatible mixture of oxysterols up-regulates 
the expression and synthesis of the scavenger receptor CD36, with consequent uptake of oxLDLs, 
involving PKC- , ERK, and the peroxisome proliferator-activated receptor  (PPAR ) pathways 
[58]. Indeed, the monocyte differentiation into macrophages observed in oxLDL-treated THP-1 
cells has been attributed to its major oxysterols, 7 -OH and 7-K [59]. Foam cell formation, a key 
process during the development of atherosclerosis, which leads to vascular inflammation, is also 
sustained by TLR4: deficiency of TLR4 significantly reduces macrophage lipid accumulation in 
vascular lesions [60]. Furthermore, the common Asp299Gly TLR4 polymorphism, which causes  
loss of function, is associated with lower plasma levels of pro-inflammatory cytokines, adhesion 
molecules and acute-phase proteins, and a decreased atherosclerosis risk [61]. 
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 The accumulation of lipids in the macrophages present at the subendothelial level might 
depend on some oxysterol profile present in the atheromasic lesion: the main cytotoxic oxysterols, 
i.e. 7-K, 7 -OH, and 5 ,6 -epoxycholesterol ( -EPOX), are potent inducers of endolysosomal 
phospholipidosis, because they trigger the formation of multilamellar cytoplasmic structures, called 
myelin figures, cointaining high levels of phospholipids [62-64]. Phospholipid accumulation has 
been shown to be connected with oxidative stress and apoptosis induced by oxysterols, and could 
contribute to in vivo vascular injury [65]. Moreover, 7-K-induced phospholipidosis involves the 
phosphatidylinositol 3 kinase (PI3K)/Akt signaling pathway, and is partially reversed by vitamin E 
in U937 monocytes [66]. Of note, endolysosomal lipid storage induces strong pro-inflammatory and 
pro-atherogenic responses in macrophages [67].  
 
Induction of other inflammatory mediators: phospholypase A2 and cyclooxigenase-2 
 
 Treatment of rat aortic SMCs with 25-OH or 22R-OH causes accumulation of group IIA 
secretory phospholipase A2 (PLA2) and increases enzyme activity, with involvement of the LXR 
pathway [68]. Oxysterols are also able to activate the cytosolic PLA2: in macrophages, activation of 
cytosolic PLA2 by 25-OH increases arachidonic acid release [69] and is involved in the initiation of 
the apoptosis pathways triggered by 7-K [70]. In agreement with these observations, eicosanoid 
production has been found to be stimulated in bovine coronary artery ECs treated with 25-OH [62]. 
In contrast, in ECs, 7-K inhibits phosphorylation of cytosolic PLA2 and arachidonic acid release, by 
altering a Ca
2+
-independent upstream step of the PI3K and ERK1/2 cascade [72]. 
 The oxysterol TRIOL enhances cyclooxygenase-2 (COX-2) expression and synthesis, 
leading to prostaglandin E2 (PGE2) production in HUVECs. This effect requires the involvement of 
PI3K/Akt and endothelial nitric oxide synthase (NOS) and the activation of p38 MAPK and NF- B 
[73]. 
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 However, despite their marked pro-inflammatory effects, in certain experimental conditions, 
oxysterols have also been reported to exert anti-inflammatory effects. For instance, LPS-induced 
TNF-  secretion was significantly decreased when human macrophages were incubated with 7 -
OH, 25-OH and 27-OH before LPS challenge [74]. Moreover, exposure of human macrophages to 
chylomicron remnant-like particles loaded with 7 -OH, but not similar particles loaded with 7-K, 
significantly reduced IL-6 and TNF-  secretion [75]. It is also reported that 22R-OH and 7-K 
inhibit protein expression of both inducible NOS and COX-2 in LPS-stimulated primary rat 
microglial cells [76]. 
 
LXR-dependent effects of oxysterols 
 
LXR has been implicated in many biological processes, ranging from regulating lipid 
metabolism to inflammation and immunity [77-79]. Of note, LXR is involved in the pathogenesis of 
cardiovascular diseases, and LXR agonists prevent development of atherosclerosis, by modulating 
metabolic and inflammatory gene expression in rodent models. Indeed, activation of LXR leads to 
maintenance of cholesterol homeostasis through transcriptional activation, and to suppression of the 
inflammatory response through transrepression. Among the oxysterol family, 20S-
hydroxycholesterol (20S-OH), 22R-OH, 24S-OH, 24S,25-epoxycholesterol (24S,25-EPOX), -
EPOX, 25-OH, and 27-OH are endogenous ligands of LXR, but 7-K and 7 -OH are not [27,80-82]. 
However, among these LXR ligands, only 27-OH appears to be present in significant amounts in 
cholesterol-loaded human macrophages, cells that play a key role in atherogenesis [83]. 
 Activation of both LXR isotypes (  and ) in cultured macrophages represses the expression 
of inflammatory mediators, such as inducible NOS, COX-2, IL-6 and IL-1 , MCP-1 and MCP-3, 
and MMP-9, in response to inflammatory stimuli, and, at the same time, it regulates the expression 
of genes involved in lipid homeostasis. In this connection, LXR appears to play a major role in 
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translating lipid signaling into inflammatory responses [77,78,84]. Activation of LXR also inhibits 
inflammatory gene expression in the aortas of atherosclerotic mice [85]. However, it has recently 
been reported that agonists of the oxysterol LXR stimulate inflammatory pathways in ECs, leading 
to the up-regulation of adhesion molecules (e.g. ICAM, VCAM), chemokines (e.g. IL-8, IL-1 ), 
transcription factors (e.g. AP-1), and enzymes (e.g. COX-2), and to the down-regulation of 
endothelial NOS, through LXR-independent mechanisms [86]. 
 Importantly, cross-talk between LXR and TLR signaling has been demonstrated in 
macrophages, as well as in aortic tissue. This cross-talk is mediated by the transcriptional factor 
IRF3, a specific effector of TLR3 and TLR4 that inhibits the transcriptional activity of LXR on its 
target promoters. Thus, activation of TLR3 and TLR4 can block the induction of LXR target genes 
by antagonizing LXR [77]. Conversely, activation of LXR by oxysterols or by synthetic agonists in 
macrophages inhibits TLR-inducible inflammatory genes, such as inducible NOS, IL-1 , MCP-1, 
by interfering with NF- B signaling [78,87]. In this regard, the repression pathways mediated by 
LXR involve the nuclear receptor co-repressor. Nuclear receptor co-repressor-deficient 
macrophages exhibit derepression of a subset of genes that are normally activated by NF- B and 
AP-1 in response to pro-inflammatory signals [88,89]. 
 
Cholesteryl ester oxidation products 
 In the lipid moiety of LDLs, cholesterol is present both in the unesterified and in the 
esterified form, i.e. bound or not to fatty acids. The atherogenic properties of oxLDLs are also 
conferred by oxidized cholesteryl esters, in which oxidation involves either cholesterol itself or 
monounsaturated fatty acids and polyunsaturated fatty acids (PUFAs), producing several products, 
including cholesteryl ester hydroperoxides [90] and core-aldehydes [91]. Of note, at least in in vitro 
models, at more advanced stages of LDL oxidation, decomposition of the initially formed 
cholesteryl ester hydroperoxides may lead to the formation of oxysterols [92,93]. 
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Induced formation of foam cells 
 
 Cholesteryl ester hydroperoxides are responsible for many of the biological activities of 
minimally oxLDLs, and they may be relevant to inflammatory activation of macrophages in 
atherosclerotic lesions [94]. Moreover, in differentiated human macrophages, it has been observed 
that oxidized derivatives of cholesteryl esters contribute to the formation of foam cells, by inducing 
scavenger receptor CD36 expression with involvement of PPAR  [95].  
 Although accumulation of cholesteryl oleate in the plasma has been reported to be a 
predictor of atherosclerosis in animal models, whereas cholesteryl esters of n-3 and n-6 PUFAs may 
provide athero-protection by reducing that accumulation [96], oxidized derivatives of cholesteryl 
ester containing n-6 PUFAs have been found in oxLDLs and in atherosclerotic lesions. In particular, 
high levels of 9-oxononanoyl cholesterol (9-ONC) and 5-oxovaleroyl cholesterol (5-OVC), 
respectively derived from linoleic acid and from arachidonic acid, have been found in oxLDLs and 
in atherosclerotic lesions [97-99]. These so-called core-aldehydes have been shown to stimulate 
adhesion molecule production by HUVECs, favoring blood monocytes and U937 cell adhesion 
[100]. Furthermore, these products can react covalently with amino groups of apoprotein B100, 
with consequent uptake of the modified oxLDLs by activated macrophages through scavenger 
receptors and foam cell formation [101].  
  
Pro-fibrogenic effect 
 
 9-ONC has also been found to stimulate expression and synthesis of TGF 1, in both 
J774.A1 murine macrophages and human U937 promonocytic cells, contributing to inflammation 
and fibrosclerosis in atherosclerotic plaques [102,103]. An increased membrane presentation of 
TGF  type II receptor has also been observed. The increased levels of the cytokine and of its 
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specific receptors in 9-ONC-treated cells appear to be mediated by the stimulation of ERK1/2 
induced by the oxidized lipid. The core-aldehyde 9-ONC might thus sustain further vascular 
remodeling due to atherosclerosis, not simply by stimulating synthesis of the pro-fibrogenic 
cytokine TGF 1 in vascular cells, but also and chiefly by enhancing the TGF 1 autocrine loop 
[103]. 
 
Lipid peroxidation-derived free aldehydes 
 
Lipids containing PUFAs are susceptible to free radical-initiated oxidation, and can 
participate in chain reactions that increase damage to biomolecules. The chain process of lipid 
peroxidation includes simultaneously generated lipid hydroperoxides and aldehydes of various 
chain lengths [104-108]. 
The enzymatic and non-enzymatic peroxidation of n-3 and n-6 PUFAs generates several 
reactive aldehyde species, which have been shown to exert regulatory roles as well as detrimental 
effects in various cell types and organs. These aldehydic end-products of lipid peroxidation are 
known to be among the molecules responsible for the pro-atherogenic effect of oxLDL.  
Peroxidation of n-3 PUFAs, such as linolenic, eicosapentaenoic, and docosahexaenoic acids, 
generates the molecule 4-hydroxy-2-hexenal (HHE). Peroxidation of n-6 PUFAs, such as 
arachidonic and linoleic acids, as well as of their 15- and 13-lipoxygenase (15-LO, 13-LO) 
metabolites (namely 15-hydroperoxyeicosatetraenoic acid and 13-hydroperoxyoctadecadienoic 
acid) yields an aldehyde with remarkable biochemical effects, namely 4-hydroxy-2-nonenal (HNE). 
Another reactive peroxidation product is 4-hydroxy-2,6-dodecadienal (HDDE), which is derived 
from 12-hydroperoxyeicosatetraenoic acid, the 12-lipoxygenase metabolite of arachidonic acid. 
These aldehydes, and in particular HNE, have multiple pathophysiological effects, due to their high 
chemical reactivity and lipophilicity, and to their formation of covalent adducts with 
macromolecules (proteins, peptides, lipids, and nucleic acids). Indeed, they react with the thiol and 
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amino groups, especially of the amino acids cysteine, histidine and lysine. The progressive 
accumulation of these adducts alters normal cell functions, and may lead to cell death [104,109-
111]. Nonetheless, at low and noncytotoxic concentrations, these molecules can act as second 
messengers in signal transduction in physiological and/or pathophysiological conditions [111-115]. 
The most representative unsaturated hydroxyalkenal in tissues and cells is HNE [116-118]. 
This aldehyde has been investigated in depth thanks to its contribution to the pathogenesis of major 
chronic human diseases, including atherosclerosis, and this molecule has been reported to possess 
both signaling and cytotoxic effects [112,116,119,120]. 
 
HNE-induced endothelial dysfunction and foam cell formation 
 
HNE can directly impair the barrier function of the endothelium by increasing its 
permeability [115]: it may induce changes in cellular thiol redox status, thus perturbing cell 
signaling pathways and leading to endothelial barrier dysfunction. Following induction of ROS, 
HNE may affect EC permeability, modulating cell-cell adhesion by suppressing focal adhesion 
kinase (FAK) phosphorylation, which in turn affects focal adhesion, adherence, and tight junction 
proteins, as well as integrins, which are natural FAK receptors [121]. Modification of cytoskeletal 
proteins, including actin and microtubules, by HNE and by other unsaturated aldehydes, plays an 
important role in regulating cell-cell contacts and endothelial barrier function [121]. HNE may 
stimulate the adhesion of macrophages to the vascular endothelium in the early stages of 
atherosclerosis, as well as that of lymphocytes, pro-inflammatory immune cells [122]. This 
aldehyde may potentiate inflammation and immune responses by inducing COX-2 and in 
consequence prostaglandin production [123]. 
In addition, HNE covalently modifies LDLs by binding to lysine and histidine residues, 
leading to adduct formation [124]; this modification could make them available to scavenger 
receptors on macrophages, thus resulting in macrophage activation and foam cell formation, a 
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crucial event in the vascular inflammation that occurs in atherosclerotic lesions. HNE also promotes 
foam cell formation, by increasing synthesis of class A scavenger receptors at the transcriptional 
level, as well as increasing synthesis of the scavenger receptor CD36 [125]. HNE also induces 
induction of CD36 in vascular SMCs by enhancing nuclear accumulation of nuclear factor E2 
related factor 2 (Nrf2), a second important transcription factor, alongside PPAR , in the induction 
of this scavenger receptor [126]. In this connection, it is also reported that nuclear translocation of 
Nrf2 requires activation of PKC [127]. After its translocation into the nucleus induced by HNE, 
Nrf2 transactivates the antioxidant responsive element (ARE). The HNE-induced Nrf2-ARE 
transcription pathway can up-regulate molecules such as thioredoxin (Trx), Trx reductase, and heme 
oxygenase-1 (HO-1), all of which are antioxidant proteins involved in the mechanisms of adapted 
cytoprotection against oxidative stress [128,129].  
 
Pro-inflammatory effects of HNE 
 
 Again in regard to inflammation, HNE has been shown to increase MCP-1 release by 
J774.A1 macrophages, by activating PKC- I and - II. The aldehyde has a dual effect on these 
enzymes: their activity is increased if cells are incubated with relatively low concentrations of HNE, 
but progressively decreases if concentrations of the aldehyde are higher [130]. Strong up-regulation 
of the inflammatory and fibrogenic cytokine TGF 1 in promonocytic and macrophagic cells 
challenged with pathophysiological concentrations of HNE has also been demonstrated [131-133]. 
It has been postulated that HNE-induced activation of NF- B mediates its pro-inflammatory 
and oxidative effects [134,135]. However, it is also reported that HNE may inactivate NF- B, by 
preventing proteolysis of the inhibitor of NF- B (I B) [136,137]. The dual effect of HNE on this 
redox transcriptional factor appears to depend on the type of cells used. For example, in THP-1 
monocytes HNE inhibited NF- B activation induced by LPS and the subsequent TNF-  release, by 
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inhibiting phosphorylation and proteasome degradation of I B [136]. Further, in human aortic ECs, 
down-regulation of NF- B activity by HNE resulted in inhibition of the expression of various 
adhesion molecules induced by inflammatory stimuli [138]. In agreement with these findings, 
activation of NF- B induced by exposure of THP-1 cells to Chlamydia pneumonia was 
significantly reduced by HNE addition [139]. Addition of HNE to macrophages did not modify the 
constitutive extent of NF- B nuclear translocation [140]. In contrast, net stimulation of NF- B by 
HNE was demonstrated in vascular SMCs [141].  
The different ways in which HNE can modulate the NF- B-signaling pathway may have a 
significant impact on atherosclerosis development. For instance, down-regulated expression of NF-
B-dependent genes, as a consequence of HNE’s inhibition of this nuclear factor, may interfere 
with the immune response and thus indirectly amplify and sustain inflammation and degenerative 
processes.  
 Conversely, marked activation of AP-1 nuclear binding by HNE has been reported. 
Activation of AP-1 has been demonstrated in murine and human macrophages [140], and in aortic 
SMCs [142]. HNE appears to up-regulate AP-1 DNA binding, mainly through activation of PKC-  
and, subsequently, through PKC-mediated activation of JNK [143].  
 
Modulation of growth factor receptors by HNE 
 
HNE interacts with epidermal growth factor receptor (EGFR) and platelet-derived growth 
factor receptor (PDGFR), which are transmembrane glycoproteins involved in various biological 
processes, as well as in the development of human diseases. In cultured human ECs, HNE was 
found to directly react with these membrane proteins, inducing formation of HNE-EGFR or HNE-
PDGFR adducts [144]. However, HNE showed a dual effect on PDGFR- , which regulates SMC 
migration and proliferation in the vascular wall. Short-term incubation of SMCs with low 
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concentrations of HNE induced autophosphorylation of PDGFR-  and activation of a signaling 
cascade involving the PI3K/Akt pathway and stimulating SMC proliferation [145]. Long-term 
incubation and high concentrations of HNE increased formation of HNE-PDGFR-  adducts and 
progressively inhibited PDGFR-  phosphorylation and SMC proliferation. The latter event may 
contribute to defective SMC proliferation, and decrease the stability of a vulnerable plaque [146].  
Exposure to this aldehyde also resulted in increased proliferation of SMCs through MAPK 
activation. In rat aortic SMCs treated with HNE, strong but transient activation of ERK1/2 
occurred, with induction of c-fos and c-jun protein synthesis, and increased AP-1 DNA binding 
activity; in addition, HNE induced PDGF-AA protein synthesis in rat aortic SMCs [142]. Again 
using SMCs, it was than shown that this aldehyde may activate not only ERK1/2 but also JNK and 
p38 MAPK [147]. Moreover, prolonged treatment of mouse aortic SMCs with a low concentration 
of HNE increased cell growth when young SMCs were used, but showed cytotoxic effects in aged 
SMCs. In young cells, the aldehyde induced strong activation of ERK and enhanced cyclin D1 
expression [148]. Activation of PDGFR-  and ERK1/2 by HNE in human coronary SMCs also 
appeared to be the key mechanism in the production of MMP-1, which plays a role in SMC 
migration into the intima and in plaque instability [149]. 
HNE treatment of murine macrophages has been observed to enhance 5-LO, following its 
regulation at the transcriptional level by EGFR, through activation of the stimulating protein-1 (SP-
1)/p38 and NF- B/ERK pathways [135]. Since HNE and 5-LO co-exist in macrophages in 
atherosclerotic lesions, it has been suggested that they may cooperate in modulating SMC 
migration, proliferation and atherosclerotic plaque instability. Indeed, the incubation of J774.A1 
macrophagic cells with HNE induces production of 5-LO derivatives. The association of these 
products increases MMP-9 secretion via activation of ERK and p38 pathways [150]. The same 
research group also demonstrated a similar synergic action between HNE and 5-LO derivatives in 
vascular SMCs, in which marked induction of MMP-2 occurred, again following activation of the 
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ERK and p38 pathways [134,151]. Moreover, HNE has also been shown to stimulate MMP-2 
production in the same type of cells, via mitochondrial ROS-mediated activation of the Akt/NF- B 
signaling pathways [134].  
 
Pro-inflammatory effects of unsaturated aldehydes other than HNE 
 
Notably, the finding that HNE and HDDE may act as endogenous ligands of PPAR  in 
vascular ECs is particularly important in view of the remarkable metabolic and regulatory functions 
that this nuclear receptor mediates. For instance, selective PPAR  ligands possess anti-
inflammatory properties [152]; other reports have shown that PPAR  also increases cholesterol 
export and represses inflammatory gene expression in macrophages [153], as well as augmenting 
fatty acid oxidation [154,155]. 
HHE, an end-product of n-3 PUFA peroxidation, is quite abundant but, due to its lower 
lipophilicity and lower reactivity, it is considered less physiologically active and less damaging than 
HNE or HDDE [104]. Further, HHE has properties in common with HNE, but there are important 
differences, particularly with regard to adduction targets and detoxification pathways [156]. It has 
been suggested that HHE may activate NF- B in vascular ECs, with a consequent increase in 
inducible NOS gene expression, which in turn leads to cell dysfunction due to excessive generation 
of nitric oxide radicals [157]. This aldehyde also appears to be responsible for EC apoptosis [158].  
Another reactive unsaturated aldehyde is acrolein, which is generated from threonine by 
neutrophil myeloperoxidase at the site of inflammation, and which has been identified as both a 
product and an initiator of lipid peroxidation [159,160]. Elevated acrolein levels have been found in 
various diseases, including atherosclerosis, and it contributes to ROS generation, which in turn may 
lead to inflammation and cell dysfunction [161]. It has been demonstrated that acrolein induces 
COX-2 expression and PGE2 production in HUVECs, through the activation of PKC, p38 MAPK, 
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and cAMP response element-binding protein (CREB). Moreover, this aldehyde inactivates Trx 
reductase, a primary antioxidant enzyme [161]. In this connection, acrolein, like HNE, reacts with 
the thiol groups of Trx1, a protein that regulates antioxidant functions in ECs. Modification of Trx1 
by either aldehydes may potentiate monocyte adhesion to ECs during the early events of 
atherosclerosis [122]. Further, exposure to acrolein induces differentiated THP-1 macrophages to 
secrete MMP-9 via a mechanism that involves xanthine oxidase activation and increased ROS 
generation [162]. 
 
Oxidized phospholipids 
 
Oxidized phospholipids (oxPLs) derive from oxidative modification of LDLs, but also from 
the membranes of cells undergoing apoptosis. Enzymatic or non-enzymatic oxidation of fatty acids 
linked to the sn-1 and sn-2 positions of glycerophospholipids leads to many different reaction 
products, depending on chain length and degree of unsaturation [111,163]. These products are 
implicated as modulators of inflammation, and increased levels of oxPLs are involved in the 
pathogenesis of various diseases, including atherosclerosis [164-166]. However, oxPLs play a dual 
role in modulating inflammation, since they may exhibit both pro-inflammatory and anti-
inflammatory effects [16,165,167,168]. 
 
Primary role in stimulating adhesion of monocytes to the endothelial barrier  
 
One major phospholipid present in minimally modified LDLs is 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC), which generates a heterogeneous group of 
oxygenated full-length products, or compounds with truncated oxidized residues present at the sn-2 
position (oxPAPC); these accumulate in atherosclerotic lesions [169,170]. The atherogenic potential 
of oxPLs, in particular of oxPAPC, has been demonstrated in cell culture studies, in terms of 
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enhanced binding of monocytes, but not of neutrophils, to oxPLs-stimulated ECs [170] and of 
concomitant induction of MCP-1 and IL-8 [171]: monocyte/EC adhesion is a hallmark of chronic 
inflammation. Regarding the mechanisms mediating adhesion of monocytes to ECs, oxPLs were 
not found to up-regulate ICAM, VCAM or E-selectin, but rather to induce MCP-1, connecting 
segment-1 and P-selectin. In this connection, oxPAPC have been shown to stimulate adhesion of 
monocytic cells through activation of 1-integrin, which subsequently binds to a splice variant of 
fibronectin, containing the sequence known as connecting segment-1 [172]. The activation of 1-
integrin by oxPLs appears to be mediated by a cAMP-dependent R-Ras/PI3K pathway [173]. Of 
note, it has also been observed that oxPAPC induces monocyte adhesion to ECs by activating the 
PGE2 receptor subtype 2, leading to increased cAMP levels and activation of PKA [174]. Another 
mechanism involves P-selectin, which is known to bind both monocytes and neutrophils to ECs. 
OxPLs up-regulates P-selectin in human aortic ECs [175] and in murine carotid arteries [176]. Up-
regulation of P-selectin protein and P-selectin-dependent adhesion of leukocytes are also reported in 
ApoE
-/-
 mouse aortic segments [177]. Moreover, it has been suggested that oxPLs could stimulate 
formation of platelet-monocyte aggregates, an event that may play a role in the pathogenesis of 
vascular diseases, by enhancing P-selectin expression [178].  
Increasing evidence also indicates that phosphatidylcholine (PC) hydroperoxide plays a role 
in atherosclerosis. In particular, it has been reported that treating THP-1 monocytic cells with PC 
hydroperoxide stimulates their adhesion to immobilized vascular EC adhesion molecules. In 
addition, THP-1 cell adhesion to ICAM-1, an effect exerted by this peroxide, was found to be dose-
dependent [179] and to require activation of GTPases of the Rho subfamily named Rac (Ras-related 
C3 botulinum toxin substrate) [180].  
 
Up-regulation of chemokines, inflammatory cytokines and growth factors  
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OxPLs, in particular oxPAPC, contribute to the recruitment of inflammatory cells in the 
atherosclerotic lesion, inducing not only adhesion molecules but also growth factors and cytokines 
in vascular ECs [181]. Moreover, induction by oxPLs of chemotactic activity in monocytes requires 
activation of MAPKs [182-184]. The induction of chemokines is regulated by genetic and/or 
epigenetic factors: in human aortic ECs derived from multiple heart transplant donors, the level of 
inflammatory gene induction by oxPLs differed. In particular, production of IL-8, but also of IL-6 
and MCP-1, was increased in those cells through regulation of the unfolded protein response 
[185,186]. Further, immunohistochemical analysis of human atherosclerotic lesions indicated 
activation of the unfolded protein response in areas containing oxPLs [186]. Importantly, it has also 
been reported that up-regulation of IL-8 and MCP-1 expression induced by oxPLs is independent of 
the classical NF- B pathway, but that it involves activation of c-Src kinase. OxPLs bind to the 
TLR4 complex and lead to rapid and transient activation of c-Src kinase, which in turn induces 
phosphorylation of the transcription factor STAT3 [187]. Subsequently, STAT3 dimerizes, 
translocates to the nucleus and induces transcription of IL-8. In ECs, oxPAPC induces the synthesis 
of chemotactic factors, such as IL-8, involving c-Src kinase-dependent activation of JAK2, which 
leads to enhanced levels of STAT3 activity in inflammatory areas of atherosclerotic lesions [188]. 
Moreover, oxPAPC may modulate cytokine expression by binding to human macrophages via the 
platelet activating factor (PAF) receptor. Occupation of the PAF receptor by oxPLs stimulates 
intracellular calcium signaling, which modifies the transcription levels of highly pro-inflammatory 
cytokines, including IL-8 [189]. Another mechanism has also been proposed: oxPAPC might 
increase IL-8 and MCP-1 expression in ECs, involving activation of PPAR  [190,191].  
The compound 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-phosphocholine (POVPC), an 
oxidatively fragmented component of oxPAPC, stimulates expression of IL-8, IL-1 , and TNF-  in 
human monocyte-derived macrophages [189]. POVPC has also been found to activate cytosolic 
PLA2 via the MAPK pathway in HUVECs, resulting in the release of free arachidonic acid [192], 
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which is used by LO to produce 12-hydroxyeicosatetraenoic acid that, in turn, contributes to 
stimulating monocyte binding to human aortic ECs [193].  
In addition, hydroxy and oxo alkenal phospholipids, another form of oxPLs, may locate at 
the surface of oxLDLs and act as ligands of the scavenger receptor CD36 on macrophages, with 
consequent uptake of oxLDLs and foam cell formation [194]. 
In monocytes, oxPLs have also been found to stimulate VEGF that, in addition to its 
angiogenic growth factor activity, is another factor involved in leukocytes’ migration [195]. In 
addition, up-regulation of VEGF induces expression of VCAM-1 and platelet endothelial cell 
adhesion molecule (PECAM-1) on the endothelium, and stimulates monocyte adhesion, leading to 
the formation of more inflamed atherosclerotic lesions in ApoE
-/-
mice [196]. Again, in human aortic 
ECs, VEGF receptor 2 is reported to regulate ERK1/2-mediated activation of the transcription 
factor sterol regulatory element-binding protein 1 (SREBP-1), and the subsequent transcription of 
tissue factor, LDL receptor, and IL-8 [197].  Endothelial NOS has been reported to play a role in the 
activation of SREBP by oxPAPC [198].  
OxPAPC may contribute to oxidative stress by inducing ROS generation, which in turn 
stimulates inflammatory gene expression. VEGF receptor 2 was found to mediate oxPAPC-induced 
recruitment of Rac1 to the NADPH oxidase-4 complex, resulting in strong ROS generation by ECs 
[199]. Another pathway used by oxPAPC to generate ROS includes uncoupled endothelial NOS 
and increased mitochondrial metabolism [200]. In parallel with an increased production of ROS, 
oxPAPC may stimulate the transcription of oxidative stress response genes, such as OKL38, a key 
regulator of important inflammatory and anti-inflammatory molecules [201]. Expression of OKL38 
has been observed to  be mediated by Nrf2 [202].  
 
Anti-inflammatory effects  
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Despite their likely implication in inflammatory reactions, oxPLs are also thought to exert 
anti-inflammatory effects in leukocytes. For example, oxPLs, acting via PGE2 receptor subtype 2, 
inhibit basal production of TNF-  and enhance production of the anti-inflammatory cytokine IL-10 
in macrophages [203]. Inhibition of IL-12 synthesis, with a concomitant increase in IL-10 levels, 
has also been observed in primary human monocytes stimulated by TLR2 and TLR1 ligands [204]. 
Furthermore, oxPLs may exert anti-inflammatory effects, by inducing drug metabolism phase II 
genes, which mediate protection from oxidative stress. Low concentrations of oxPLs do not damage 
cells, but induce antioxidant enzymes, such as HO-1, known for its anti-inflammatory activity 
[205]. Induction of HO-1 expression by oxPAPC in HUVECs involves the phosphorylation of 
CREB, which is also dependent on MAPK pathways [206]. COX-2 is another enzyme involved in 
oxPL-mediated anti-inflammatory signaling. The expression of COX-2 appears to be modulated by 
oxPLs, in a cAMP-response-element-binding-protein-dependent and PPAR -dependent manner 
[207]. OxPLs may also increase NO production, with possible anti-inflammatory effects, including 
down-regulation of adhesion molecules and chemokines, as well as inhibition of leukocyte 
migration [198].  
 
Modulation of vascular smooth muscle cell phenotype 
 
Increasing experimental evidence suggests that oxPLs may play a role in phenotypic 
modulation of vascular SMCs. It has been found that oxPAPC and POVPC switch the phenotype of 
SMCs to an inflammatory state. Suppressed transcription of the SMC differentiation marker genes 
induces expression of pro-inflammatory genes, enhances the rate of cellular proliferation, and 
increases synthesis of extracellular matrix proteins; further, oxPLs can also suppress expression of 
smooth muscle actin and myosin heavy chain, and increase expression of MCP-1 and MCP-3 [208]. 
OxPL derivatives POVPC and 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine (PGPC) 
have been shown, both in vivo and in vitro, to induce vascular SMC proliferation, by reducing 
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expression levels of connexin 43, another important factor in the pathogenesis of atherosclerosis 
[209]. In addition, POVPC may alter extracellular matrix production and stimulate vascular SMC 
migration [210]; it has also been shown that oxPLs stimulate expression of the metalloproteinase 
known as disintegrin, and that of metalloproteinase with thrombospondin motifs-1 (ADAMTS-1) 
[195]. These observations suggest a role of oxPLs in plaque destabilization. 
 
Effects on endothelial cells 
 
OxPLs, which accumulate in atherosclerotic lesions, may also exert intraplaque angiogenetic 
effects, by stimulating production of VEGF, IL-8, and COX-2-derived prostaglandins that act in 
concert to induce the angiogenic switch in ECs [195]. A later study found that oxPLs induced up-
regulation of VEGF by activating transcription factor 4 (ATF4)-dependent transcription [186]. 
Moreover, it has recently been reported that oxPLs regulate expression of ATF4 and VEGF in ECs, 
through a Nrf2-dependent mechanism [211].  
OxPLs may have a dual effect on barrier function. Some sn-2 fragmented oxPLs, such as 
POVPC and PGPC, increase endothelial permeability even at low concentrations [212,213]. In 
contrast, both oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoserine (oxPAPS) and 
oxPAPC exhibit potent barrier-protective effects by attenuating the agonist-induced EC 
permeability triggered by transient activation of the Rho pathway [214]. Indeed, treatment of the 
endothelium with oxPAPC suppresses Rho-dependent induction of EC permeability, as stimulated 
by inflammatory molecules or other agonists, such as IL-6, thrombin, and LPS [212,214]. It has 
also been observed that, during protection of the endothelial barrier, oxPLs cause specific 
rearrangements of the cytoskeleton, also enlarging the adherens junctions and their colocalization 
with focal adhesion protein complexes [215]. 
 Very recently, to elucidate the major pathways involved in oxPAPC action, a systems 
analysis of endothelial cell gene expression after exposure to these products was performed 
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[201,216]. This network analysis provided novel hypotheses about molecular interactions, as well 
as candidate molecular regulators of inflammation. In particular, it was found that oxPLs activate 
specific signaling pathways, and regulate a large number of genes involved in homeostasis of the 
cytoskeleton, junctional components, and tyrosine kinases, all cell elements that may contribute to 
the phenotypic and molecular changes observed in ECs treated with oxPAPC.  
 
Other oxPLs derivatives: lysophospholipids 
 
Hydrolysis of oxPLs by secretory PLA2, or by lipoprotein associated-PLA2, yields bioactive 
lipids that include oxidized fatty acids and lysophospholipids, such as lyso-phosphatidylcholine 
(lyso-PC) [217]. Lyso-PC, the precursor of lysophosphatidic acid, is found in atherosclerotic lesions 
and may in principle exert pro- or anti-atherogenic effects, depending on the arterial cell type and 
inflammation status. However, lyso-PC has been consistently shown to be associated with 
endothelial dysfunction in early coronary atherosclerosis in humans, thus supporting a role of these 
phospholipases in the pathogenesis of vascular inflammation and atheromasic lesions [218].  
Various signaling effects relevant to atherosclerosis progression are reported to be exerted 
by lyso-PC. This lysophospholipid has been shown to: i) increase intracellular Ca
2+
, mainly by 
activating the PAF receptor, in macrophagic cells [219]; ii) modulate the MAPK pathway in 
macrophages [220]; iii) induce pro-inflammatory cytokines in circulating mononuclear cells, by 
activating the PAF receptor [221]; iv) activate G-protein-coupled receptor A, a molecule involved 
in immune cell migration and apoptosis, both in T lymphocytes and in macrophagic cells [222,223]. 
Further, lyso-PC has also been found to stimulate the release of pro-inflammatory cytokines, such 
as IL-8 and IL-6, and of growth factors, such as bFGF, in human coronary artery SMCs [224]. Even 
nanomolar concentrations of lyso-PC are able to stimulate cytokine expression and monocyte 
recruitment [225]. In addition, monocyte migration driven by lysophospholipids appears to 
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implicate a certain protein kinase D (PKD)-dependent signaling pathway [226] and to require non-
selective cation channel activation, independent of G-protein and phospholipase C [227]. 
 
Arachidonic acid derivatives in atherosclerosis  
 
Among the oxidized lipid products implicated in atherogenesis, there is a large group of 
potent bioactive lipids called eicosanoids (prostanoids, isprostanes, and leukotrienes) which derive 
from the oxidation of arachidonic acid, a component of membrane phospholipids released by PLA2. 
Prostanoids and leukotrienes are formed enzymatically from arachidonic acid, by COX and LO, and 
the various sub-classes are generated by distinct enzymatic pathways. Isoprostanes are a class of 
prostaglandin-like products formed via free-radical-mediated oxidation of arachidonic acid, 
esterified in membrane phospholipids. All these lipid mediators are consistently observed in 
atherosclerotic lesions where, together with the oxLDL-derived oxidized lipids, they contribute to 
the inflammatory responses and to plaque progression [228-232]. 
Of note, LDL lipid oxidation products could regulate eicosanoid production, by modulating 
the enzymatic degradation of arachidonic acid via cyclooxygenases and lipoxygenases. In 
particular, oxLDL has been shown to downregulate inducible COX-2 in human macrophages 
exposed to LPS. This finding may support the hypothesis that transformation of macrophages into 
foam cells results in the attenuation of the inflammatory response, thus contributing to the 
progression of atherogenesis [233]. Inhibition of COX-2 by oxLDL might also promote thrombotic 
events, by disturbing the balance between platelet thromboxanes (TX) and PG [234].  In contrast, 
the aldehyde HNE is reported to induce gene expression of COX-2 [235]. It has also been 
hypothesized that 12-LO and 15-LO might directly contribute to LDL oxidation [236]. 
 
Prostanoids 
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Prostanoids, consisting of PG and TX, are produced from arachidonic acid by the sequential 
actions of PLA2, COX-1 or COX-2, and the respective prostanoid synthases. They exert a variety of 
biological activities in the atheromasic lesion, by binding to specific G-protein-coupled receptors, 
known as the thromboxane receptor (TP) and the prostaglandin receptors (e.g. EP, IP), that are 
expressed in the target cells [237,238]. These receptors are highly expressed in ECs and SMCs, as 
well as in platelets and monocytes/macrophages. Of note, a significant increase in TP receptor 
expression and activation induces the expression of adhesion molecules, such as ICAM-1 and 
VCAM-1, in ECs [239,240], as well as inducing IL-1 -dependent VCAM-1 expression in vascular 
SMCs [241] which facilitate the migration of monocytes to the vessel wall.  
Prostanoids are known to promote the initiation and progression of atherosclerosis, not only 
via platelet activation, but also through leukocyte-endothelial adhesion and vasoconstriction. Of 
note, PGI2 and TXA2, the major prostanoids in cardiovascular diseases, have opposing actions: PGI2 
induces vascular relaxation, and potently inhibits platelet activation and vascular SMC proliferation, 
whereas TXA2 is a potent vasoconstrictor, a strong platelet activator, and it also stimulates vascular 
SMC proliferation. Because of their opposed actions, the balance between these two bioactive lipids 
is known to be a critical factor causing a tendency to thrombosis. Moreover, it has been suggested 
that PGI2 suppresses the development of vascular remodeling, due to its inhibitory actions on 
vascular SMC proliferation and on the platelet function [242] but also due to its regulatory role over 
endothelial progenitor cells, which are known to be the cells involved in reendothelialization, a 
process which limites vascular remodeling [243]. PGI2 is also reported to play a role in the pro-
angiogenic function of endothelial progenitor cells, consisting in proliferation of these cells and 
tube and capillary formation [244]. In contrast, platelets activated by TXA2 serve as a source of 
growth factors, pro-inflammatory cytokines, and chemokines [245]. TXA2 and its TP receptor are 
also critical to atherogenesis, promoting leukocyte recruitment and adhesion through enhancement 
of the transmembrane chemokine fractalkine (CX3CL1) [246].  
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The prostanoid 15-deoxy- 12,14-prostaglandin J2 (15d-PGJ2) has also been shown to 
inhibit the cytokine-induced expression of several adhesion molecules, including E-selectin, ICAM-
1 and VCAM-1. For example, 15d-PGJ2 inhibits E-selectin expression via PPAR -dependent 
transcriptional induction of ATF3 [247]. Furthermore, 15d-PGJ2 has a dual action on ICAM-1 in 
ECs: it directly induces ICAM-1 expression through an increase of AP-1 binding to its promoter, 
but it simultaneously blocks TNF- -induced ICAM-1 expression through inhibition of NF- B DNA 
binding. Both these actions are PPAR -dependent [248]. TNF- -induced VCAM-1 expression is 
also blocked by activation of the transmembrane PGI receptor, known as IP [249]. 
In the progression of atherosclerotic lesions, vascular SMCs migrate to the subendothelial 
space, where they proliferate and secrete extracellular matrix proteins. This process is partly 
mediated by endothelial production of PDGF, and 15d-PGJ2 has been reported to inhibit PDGF 
synthesis in ECs, by decreasing the expression of the SP-1 transcription factor [250]. Of note, it has 
also been demonstrated that overexpression of COX-2 and of microsomal PGE synthase 1 play key 
roles in plaque instability, through enhanced MMP generation and activity [251]. In this connection, 
the prostaglandin PGE2 might contribute to plaque destabilization, by inducing MMP-2 and MMP-9 
activity in the macrophages present in the shoulder of atherosclerotic plaques [252,253]. In addition, 
PGE2 could trigger neovascularization in the lesion, which enhances plaque growth and instability, 
by acting directly on ECs and inducing VEGF secretion through activation of ERK2 and JNK1 
[254]. 15d-PGJ2 might also have pro-angiogenic activity, by up-regulating VEGF expression with 
the involvement of PPAR  [255]. PGE2 might also exert pro- or anti-inflammatory effects, 
depending on its receptor subtypes (EP), the cell type, and the activation context. For example, it 
has been shown that EP3, a receptor for PGE, mediates PGE2-exacerbated atherothrombosis [256] 
while the EP4 receptor inhibits production of chemokines by macrophages [257]. However, it is 
also reported that the EP4 receptor is involved in PGE2-dependent MMP overexpression in human 
atherosclerotic plaques [258]. 
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Isoprostanes 
 
Several lines of evidence suggest that isoprostane generation may reflect oxidative stress 
and inflammation in experimental and human atherosclerosis [230,259]. Moreover, isoprostanes are 
useful biomarkers of cardiovascular diseases [260]. Some F2-isoprostanes, in particular 8-iso-
PGF2 , have been demonstrated to have biological activities that may contribute to the progression 
of vascular damage [259]. 
Concerning the pro-inflammatory effects of F2-isoprostanes, it has been observed that these 
arachidonic acid derivatives promote the formation of TXA2, platelet activation, mitogenesis of 
vascular SMCs, proliferation of fibroblasts and ECs, and that they increase endothelin 1 expression 
in aortic ECs. All their biological activities involve activation of the TP receptor [261,262]. In 
particular, during promotion of platelet activation and adhesion, 8-iso-PGF2 , induced activation of 
tyrosine kinase and of p38 MAPK [263] whereas in SMCs F2-isoprostanes activated PKC, as well 
as Rho/Rho kinase and tyrosine kinases. In addition, activation of ERK1/2 by 8-iso-PGF2  has been 
implicated in SMC proliferation while activation of p38 MAPK by the same isoprostane has been 
shown in the pro-adhesive phenotype of ECs [264,265]. Of note, 8-iso-PGF2 has been observed to 
induce monocyte adhesion to ECs, although it was unable to induce the expression of E-selectin or 
VCAM-1: it induced monocyte adhesion via TP receptor and PKA/MAPK pathway activation 
[265]. Moreover, the isoprostane 8-iso-PG2  may induce formation of foam cells, by inducing 
scavenger receptor A type 1 expression, and it may stimulate oxLDL to induce MMP-9 and TIMP-1 
gene expression in THP-1 cells [266]. 
 
Leukotrienes 
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Leukotrienes (LTs) are generated from arachidonic acid by the 5-, 12-, and 15-LO pathways 
[232]. Several studies have suggested the existence of a potential link between the LT signaling 
cascade and the progression of atherosclerosis. LTs exert pro-inflammatory effects, by interacting 
with specific LT receptors expressed in inflammatoty cells within vascular wall [267].  
Among LTs, LTB4 produces increased leukocyte adhesion to the endothelium, followed by 
transendothelial migration. This inflammatory effect is mediated through the LTB4-specific G-
protein-coupled receptors, the BLT1 and BLT2 receptors [268]. In HUVECs, LTD4 has been found 
to induce endothelial P-selectin expression through CysLT2 receptor activation [269] and levels of 
various chemokines and of IL-8 were enhanced after stimulation of HUVECs with LTD4 [270,271]. 
It has also been found that, within human atherosclerotic lesions, SMCs express receptors 
for LTB4, mediating migration and proliferation of vascular SMCs [272]. Migration and 
proliferation of vascular SMCs appear to be modulated by 3-integrin-associated signaling pathway 
activation, including FAK phosphorylation, mobilization of the actin cytoskeleton, association of 
FAK to PI3K, ERK phosphorylation, and NF- B activation [273]. Regarding the NF- B 
transcriptional factor, in cultured monocytic cells it has been found that LTB4 phosphorylates 
MAPKs and stimulates NF- B activity, through the BLT1 and BLT2 membrane receptors. 
Activation of the transcriptional factor contributes to NF- B-dependent inflammatory responses 
[274]. 
It is also reported that 15-hydroxyeicosatetraenoic acid, generated by 15-lypoxygenase 2, 
plays a role in the regulation of vascular SMC migration and neointima formation, involving 
CREB-mediated IL-6 expression [275]. Another metabolite of 12- and 15-LO, 12-
hydroxyeicosatetraenoic acid, can contribute to vascular SMC migration, by inducing MCP-1 and 
IL-6 expression, through Src tyrosine kinase signaling activation [276]. Further, 12-
hydroxyeicosatetraenoic acid might activate PKC- , which forms a complex with RhoA; this 
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complex is required for activation of NF- B and the subsequent stimulation of ICAM expression, 
which events favor monocyte adhesion to the endothelium [277]. 
Furthermore, LTB4 has been shown to increase the intima/media thickness and expression of 
MMP-2 and MMP-9 in human arteries [278]. Again, production of LTB4 and signaling through the 
BLT1 receptor have recently been shown to be essential for MMP-2 secretion in vascular SMCs 
treated with HNE, leading to atherosclerostic plaque instability [279]. In this connection, the 
colocalization of 5-LO/LT generation with MMP in human carotid atherosclerotic lesions is 
reported [280]. 
 
Conclusions 
 
 All of the principal events in the multistep process of atherosclerosis, from initial EC 
damage, to atheroma development and progression, until its possible rupture, are now clearly 
recognized, and some insight into the relevant molecular mechanisms and cellular interplay has 
been achieved. 
 LDL lipid oxidation products, such as oxysterols, oxidized phospholipids, free and core-
aldehydes, as well as lyso-PC, have all been shown to accumulate in atherosclerotic lesions, 
pointing to these lipids as important factors, not only in initiating but also in promoting the 
inflammatory process underlying atherosclerosis. Especially in the last decade, significant progress 
has been made in elucidating the role of these lipid oxidation products in cell signaling and gene 
transcription, related to (i) activation of ECs and SMCs, (ii) foam cell formation, extracellular 
matrix deposition and arterial wall remodeling, and (iii) modulation of the chronic inflammatory 
reactions that occur during development of the atherosclerotic lesion. 
 Figure 1 schematically depicts the putative involvement of oxidized lipids in the various 
steps of atherosclerosis. Current knowledge of oxLDL-mediated cell signaling definitely points to 
oxPLs as the pivotal molecules among LDL lipid oxidation products promoting endothelial cell 
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dysfunction. Its derivative compound lyso-PC also appears to be implicated in this early step of 
atherogenesis. Because of their ability to up-regulate MMP, oxPLs might also contribute to the 
progression of atherosclerotic lesions, especially those becoming vulnerable and unstable. However, 
a major role in the inflammation-driven formation of atheroma appears likely to be ascribable to 
oxysterols and to certain aldehydic end-products of PUFA oxidation, in particular to HNE. Both 
types of compounds have been shown to be crucially involved in foam cell formation, through net 
overexpression of the CD36 scavenger receptor; they are also very probably involved in up-
regulating macrophage-SMC cross-talk, mainly through overexpression of the TGF  profibrogenic 
cytokine. In this connection, the demonstrated ability of the cholesteryl linoleate oxidation product 
9-ONC to increase steady-state levels of both TGF  and TGF  receptors, in cells of the 
macrophage lineage, also appears interesting. Here, too, oxysterols, and less obviously free 
aldehydic products like HNE, are strong candidates for a key role in the process leading to the 
instability and rupture of the atherosclerotic plaque, because of their marked pro-apoptotic effect, 
and above all because of their demonstrated ability to up-regulate expression and activity of 
macrophage MMP-9, while constitutive levels of its specific inhibitors TIMP-1 and TIMP-2 remain 
unchanged. 
 Moreover, derivatives of arachidonic acid oxidation, besides affecting the initiation and 
progression of atherosclerotic lesions, play key roles in vascular tone modulation and vascular 
remodeling, mainly by regulating cell proliferation, platelet function and matrix deposition.   
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Abbreviations: 5-OVC, 5-oxovaleroyl cholesterol; 7 -OH, 7 -hydroxycholesterol; 7 -OH, 7 -
hydroxycholesterol; 7-K, 7-ketocholesterol; 9-ONC, 9-oxononanoyl cholesterol; 15d-PGJ2, 15-
deoxy- 12,14-prostaglandin J2; 20-OH, 20-hydroxycholesterol; 22-OH, 22-hydroxycholesterol; 24-
OH, 24-hydroxycholesterol; 24S,25-EPOX, 24S,25-epoxycholesterol; 25-OH, 25-
hydroxycholesterol; 27-OH, 27-hydroxycholesterol; -EPOX, 5 ,6 -epoxycholesterol; -EPOX, 
5 ,6 -epoxycholesterol; AP-1, activator protein-1; ARE, antioxidant responsive element; ATF, 
activating transcription factor; bFGF, basic fibroblast growth factor; BLT, LTB receptor; COX, 
ciclooxygenase; CREB, cAMP response element-binding protein; ECs, endothelial cells; EGFR, 
epidermal growth factor receptor; EP, PGE receptor; ERK, extracellular signaling-regulated kinase; 
FAK, focal adhesion kinase; HDDE, 4-hydroxy-2,6-dodecadienal; HHE, 4-hydroxy-2-hexenal; 
HNE, 4-hydroxy-2-nonenal; HO-1, heme oxygenase-1; HUVECs, human umbilical vascular 
endothelial cells; ICAM, intercellular adhesion molecule; I B, inhibitor of NF- B; IL, interleukin; 
IP, PGI receptor; JAK, Janus kinase; JNK, c-Jun-N-terminal kinase; LDLs, low-density lipoprotein; 
LO, lipoxygenase; LPS, lipopolysaccharide; LT, leukotriene; LXR, liver X receptor; Lyso-PC, lyso-
phosphatidylcholine; MAPKs, mitogen activated protein kinases; MCP-1, monocyte chemotactic 
protein-1; MIP-1 , macrophage inflammatory protein-1 ; MMP, metalloproteinase; NF- B, 
nuclear factor- B; NOS, nitric oxide synthase; Nrf2, nuclear factor E2 related factor 2; ox LDLs, 
oxidized low-density lipoproteins; oxPLs, oxidized phospholipids; PAF, platelet activity factor; 
PAPC, 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine; PAPS, 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphoserine; PDGFR, platelet-derived growth factor receptor; PG, 
prostaglandin; PGPC, 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine; PI3K, 
phosphatidylinositol 3-kinase; PK, protein kinase; PLA2, phospholipase A2; POVPC, 1-palmitoyl-2-
(5-oxovaleryl)-sn-glycero-phosphocholine; PPAR, peroxisome proliferator-activated receptor; 
PUFAs, polyunsaturated fatty acids; RAC, Ras-related C3 botulinum toxin substrate; ROS, reactive 
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oxygen species; SMCs, smooth muscle cells; SP-1, stimulatory protein-1; SREBP-1, sterol 
regulatory element-binding protein 1; STAT, signal transducer and activator of transcription; 
TGF 1, transforming growth factor 1; TIMP, tissue inhibitor of metalloproteinase; TLR, Toll-like 
receptor; TNF- , tumor necrosis factor- ; TP, thrompoxane receptor; TRIOL, cholestan-3 ,5 ,6 - 
triol; Trx, thioredoxin; TX, thromboxane; VCAM, vascular cell adhesion molecule; VEGF, vascular 
endothelial growth factor. 
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Figure caption  
 
Figure 1. Inflammation-dependent progression of the atherosclerotic process: putative differential 
involvement of the various LDL lipid oxidation products and of arachidonic acid derivatives. 
Abbreviations used: oxPLs, oxidized phospholipids; lyso-PC, lysophosphatidylcholine; HNE, 4-
hydroxy-2-nonenal. 
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